SCHEMBL21971017

SCHEMBL21971017

C=C(C)c1ccc(CC)cc1F

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.41
MAOB P27338 2/20 0.36
RARB P10826 2/20 0.36
RARA P10276 1/20 0.36
RARG P13631 1/20 0.36
MAP2K2 P36507 1/20 0.35
MAP2K1 Q02750 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2A6 P11509 1/20 0.35
MAOA P21397 1/20 0.35
TAAR1 Q96RJ0 1/20 0.33
LMNA P02545 1/20 0.33
EPHX2 P34913 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
METAP2 P50579 1/20 0.33
LPL P06858 1/20 0.32
LIPG Q9Y5X9 1/20 0.32
RXRA P19793 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24358443 0.85 CNR1 (0.43) MAOBRARBRARARARGLPL
SCHEMBL20794208 0.85 TRPA1 (0.41) TRPA1MAP2K2MAP2K1CYP1A2CYP2A6
SCHEMBL14193595 0.85 TRPA1 (0.41) TRPA1MAOBRARBRARARARG
SCHEMBL20156497 0.83 TRPA1 (0.39) TRPA1MAOBRARBRARARARG
SCHEMBL19446943 0.83 LOXL2 (0.39) MAOBMAOATAAR1
SCHEMBL23891741 0.81 RARB (0.54) RARBRARARARGLMNALPL
SCHEMBL14011194 0.81 MAOB (0.54) TRPA1MAOBRARBRARARARG
SCHEMBL24535863 0.80 MAOB (0.40) MAOBRARBRARARARGMAOA
SCHEMBL19415763 0.78 TRPA1 (0.42) TRPA1RARBCYP1A2CYP2A6LMNA
SCHEMBL1363368 0.78 TRPA1 (0.42) TRPA1CYP1A2CYP2A6LMNAMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 US disclosed
EP-3439477-B1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2020-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 TRPA1 4247/4885MAOB 1635/4885RARB 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.